Core Insights - The Beauty Health Company has launched the Hydrafacial HydraFillic with Pep9™ Booster, a new skin treatment designed to visibly improve fine lines, wrinkles, and overall skin health through a proprietary complex of nine peptides [1][19] - The product aims to meet the rising consumer demand for non-invasive treatments that address aging signs and enhance skin health, as 81% of beauty consumers prioritize fine lines and wrinkles as their main skin concern [2][3] Product Details - The HydraFillic with Pep9™ Booster is clinically proven to enhance skin appearance, hydration, and barrier strength, resulting in a firmer and more youthful complexion [1][19] - Clinical testing showed significant improvements in skin firmness (100%), overall glow (96%), and reduced appearance of fine lines (83%) among participants after treatment [6][9] - Key ingredients include a proprietary complex of nine peptides, Triple Hyaluronic Acid Complex, and fruit extracts, which work synergistically to improve skin hydration and minimize aging signs [7][8] Market Context - The launch reflects the company's commitment to innovation in non-invasive aesthetic treatments, leveraging advanced device technology and novel skincare formulations [1][3] - The HydraFillic with Pep9™ Booster is positioned to empower providers to customize treatments based on individual client needs, aligning with current aesthetic trends focused on longevity and skin health [2][4]

1Company Data. 2Ipsos Study 2024. Base: Consumers of the aesthetic and professional beauty category (n=1000); Brand Aided Awareness. Conversion defined as % of respondents who are aware of and have tried a given brand. 3RealSelf as of April 2025. LONG BEACH, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- The BeautyHealth Company (NASDAQ: SKIN), home to flagship brand Hydrafacial™, recently achieved a major milestone with 35,000 Hydrafacial devices installed worldwide, reinforcing its market leadership in the hyd ...

Goldman Sachs is acting as exclusive financial advisor and Latham & Watkins LLP served as transaction counsel to BeautyHealth. Additional information regarding this announcement may be found in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission. Refinancing extends maturity of existing debt and strengthens Company's financial position to advance growth strategy Forward-Looking Statements LONG BEACH, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:S ...

First Quarter 2025 Earnings Presentation May 8, 2025 Disclaimer This Presentation contains certain forward-looking statements. These statements may relate to, but are not limited to, expectations of future operating results or financial performance of The Beauty Health Company (the "Company"), capital expenditures, the introduction of new products, market strategy and the ability to execute certain strategic initiatives. Some of the forward-looking statements can be identified by the use of forward- looking ...

Core Insights - The Beauty Health Company reported strong execution and momentum in its transformation strategy, exceeding revenue and adjusted EBITDA guidance despite macroeconomic pressures impacting device sales [2][5] - The company is transitioning its China operations to a distributor model and relocating production to the U.S. to mitigate tariff risks, aiming to enhance profit margins and shareholder value [2][5] Financial Performance - Net sales for Q1 2025 were $69.6 million, a decrease of 14.5% compared to Q1 2024, primarily due to lower delivery systems net sales [7][10] - Gross margin improved to 69.8% in Q1 2025 from 59.4% in Q1 2024, with adjusted gross margin at 71.9% compared to 63.4% in the prior year [7][10] - The company reported a net loss of $10.1 million in Q1 2025, compared to a net loss of $0.7 million in Q1 2024 [10][20] Operational Metrics - Delivery systems net sales were $20.2 million in Q1 2025, down from $35.8 million in Q1 2024, with total delivery systems sold decreasing from 1,417 to 862 units year-over-year [3][12] - Consumables net sales increased to $49.4 million in Q1 2025 from $45.6 million in Q1 2024, supported by an active install base growth from 32,530 to 35,014 units [3][5] Guidance and Outlook - The company updated its financial guidance for Q2 2025, projecting net sales between $71 million and $76 million and adjusted EBITDA between $2 million and $4 million [9][11] - For the fiscal year 2025, net sales are expected to be between $270 million and $300 million, with adjusted EBITDA projected between $15 million and $25 million [9][11]

Core Viewpoint - The Beauty Health Company will report its first quarter 2025 financial results on May 8, 2025, and will host an investor conference call shortly after the announcement [1]. Group 1: Financial Reporting - The financial results will be released after market close on May 8, 2025 [1]. - An investor conference call is scheduled for 4:30 p.m. Eastern Time on the same day [1]. Group 2: Investor Relations - A live webcast of the investor call will be available on the company's investor relations website [2]. - A recording of the call will be accessible approximately three hours after its conclusion [2]. Group 3: Company Overview - The Beauty Health Company (NASDAQ: SKIN) focuses on skin health experiences through its flagship brand Hydrafacial™ and other brands like SkinStylus™ and Keravive™ [4]. - The company aims to personalize skin health for diverse demographics and is committed to positive community and environmental impact [4].